Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer

EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024

Now Viewing

EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

EP: 4.Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

EP: 5.NCCN Guidelines for Early-Stage Breast Cancer: Abemaciclib and Ribociclib

EP: 6.Exploring Results from CAPItello-291 Trial

EP: 7.Exploring Biomarker Testing and Personalized Treatments in Breast Cancer

EP: 8.NCCN Guidelines Revisions and ASCO 2024 Research Outlook

EP: 9.Emerging Breast Cancer Therapies and Closing Thoughts

1. What are the current guideline-recommended systematic treatments for HR-positive/HER2-negative (HR+/HER2-) breast cancer?
2. What are some of the differences between the CDK 4/6 inhibitors used in the management of HR+/HER2-? What factors drive treatment decision-making between available options? 

Related Videos

Related Content

Advertisement

July 22nd 2025

Total Joint Arthroplasty Outcomes Comparable for Patients With Osteoarthritis Regardless of Housing Status

Brooke McCormick

Researchers found no significant differences in surgical outcomes or follow-up between housed and unhoused patients with osteoarthritis undergoing total joint arthroplasty, suggesting the procedure is safe and effective regardless of housing status.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 18th 2025

Higher BMI Linked to Lower Mortality Rate, Fewer Complications in Non-CF Bronchiectasis

Brooke McCormick

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while being underweight increases health complications.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 16th 2025

Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

Mary Caffrey

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

July 15th 2025

Potential Link Found Between Obesity and Myasthenia Gravis Exacerbation

Maggie L. Shaw

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of Daily Living response, and Minimal Symptom Expression.

Related Content

Advertisement

July 22nd 2025

Total Joint Arthroplasty Outcomes Comparable for Patients With Osteoarthritis Regardless of Housing Status

Brooke McCormick

Researchers found no significant differences in surgical outcomes or follow-up between housed and unhoused patients with osteoarthritis undergoing total joint arthroplasty, suggesting the procedure is safe and effective regardless of housing status.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 18th 2025

Higher BMI Linked to Lower Mortality Rate, Fewer Complications in Non-CF Bronchiectasis

Brooke McCormick

Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while being underweight increases health complications.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 16th 2025

Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

Mary Caffrey

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

July 15th 2025

Potential Link Found Between Obesity and Myasthenia Gravis Exacerbation

Maggie L. Shaw

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of Daily Living response, and Minimal Symptom Expression.